-
Deere & Co. Earnings Preview: Solid Results Expected, But Don't Expect Share Price Pop
Tuesday, November 21, 2023 - 2:23pm | 518Read More...Deere & Company reports its fourth-quarter earnings on Nov. 22 against the backdrop of a share price that has fallen 15% in the past four months. But could this be an opportunity to buy? Analysts polled by Zacks Investment Research have forecast Deere & Company (NYSE:DE) earnings per share...
-
ROBO Global CIO, Zacks Stock Strategist Join Benzinga's PreMarket Prep Wednesday
Wednesday, December 26, 2018 - 7:47am | 387Read More...ROBO Global CIO Bill Studebaker and Zacks Investment Research stock strategist Tracey Ryniec will join Benzinga's PreMarket Prep program Wednesday morning as the markets return from the Christmas holiday and a rocky Monday trading session. Here's what listeners have to look forward to:...
-
Despite Department Of Justice Investigation, Now May Be The Time To Buy Generic Drug Stocks
Friday, November 4, 2016 - 1:53pm | 563Read More...Public outrage is nothing new for the pharmaceutical industry this year. Between the criticism over Turing, and later Mylan, drug price hikes are clearly a pressure point in the American zeitgeist. On Thursday, it was revealed that U.S. prosecutors were set to file charges in December following...
-
Chipotle Gaining Market Share At McDonald's Expense?
Wednesday, July 23, 2014 - 3:54pm | 306Read More...Even as the Chipotle Mexican Grill (NYSE: CMG) grew same-store sales 17.3 percent in the recent quarter, McDonald's (NYSE: MCD) fell as much as three percent. Chipotle's gains "point to a longer-term trend of fast casual chains like Chipotle and Panera Bread Co. growing market...
-
3 Ways Robots Will Benefit Mass Journalism
Wednesday, July 2, 2014 - 12:39pm | 1063Read More...The Associated Press made a historic announcement this week that it would be using automation technology to write company earnings reports. Many are asserting that this decision indicates that another middle-class job is being replaced by technology, that writers will soon be taken...
-
3 Overseas Income ETFs To Boost Your Portfolio Yield
Wednesday, June 25, 2014 - 3:22pm | 544Read More...The search for yield has ETF income investors turning their focus away from high-priced U.S. assets to more attractive opportunities overseas. International markets represent new areas for capital infusion that have yet to rise to the lofty valuations of their domestic counterparts....
-
Analyst Color On Alcoa Ahead Of Earnings Report
Tuesday, April 8, 2014 - 11:18am | 781Read More...Alcoa announces earnings after the close Tuesday, April 8. Pundits consider this the unofficial start to the earnings season. Analysts expect Alcoa to report first quarter EPS of $0.05 on revenue of $5.56 billion, compared to last year’s EPS of $0.11 on revenue of $5.83 billion...
-
Coca-Cola Reports Decline In Carbonated Beverage Sales
Wednesday, February 19, 2014 - 1:46pm | 307Read More...Coca-Cola (NYSE: KO) released its full-year and fourth quarter sales Tuesday. In the report, the company disclosed that global volume had increased, but profits fell short for carbonated beverage sales in North America. Coca-Cola reported that sales volume declined one percent in North America for...
-
Small Cap Analysis: AK Steel's Position for 2013 (AKS)
Tuesday, June 11, 2013 - 1:26pm | 509Read More...AK Steel (NYSE: AKS) produces flat rolled carbon, stainless and electrical steels and tubular products. The rolled steel products are especially high quality, and electrical steels are among the most efficient. The company operates nine plants in the United States, and steel trading companies in...
-
Zacks Downgrades Alexza Pharmaceuticals to Neutral
Thursday, December 8, 2011 - 12:26pm | 27Read More...Zacks Investment Research has downgraded Alexza Pharmaceuticals (NASDAQ: ALXA) from Outperform to Neutral and has established a $1.50 price target.
-
China Medical Technologies—Is This Another Chinese Fraud?
Tuesday, December 6, 2011 - 12:35pm | 531Read More...Glaucus Research released an explosive report exposing alleged fraudulent transactions on the part of China Medical Technologies (NASDAQ: CMED). Compelling evidence suggests that CMED deliberately overpaid—to the tune of $20-23 million—for a company which its own Chairman was a stakeholder. The...
-
Zacks Upgrades First Business Financial Services to Outperform, $19 PT
Wednesday, November 2, 2011 - 12:45pm | 29Read More...Zacks Investment Research has upgraded First Business Financial Services (NASDAQ: FBIZ) from Neutral to Outperform and has established a $19 price target.
-
Zacks Initiates FutureFuel Corporation at Outperform, $16 PT
Friday, September 30, 2011 - 6:34am | 25Read More...Zacks Investment Research has initiated coverage on FutureFuel (NYSE: FF) with an Outperofrm rating and $16 price target.
-
Zacks Upgrades S&W Seed Company to Outperform, $7 PT
Monday, September 26, 2011 - 12:10pm | 28Read More...Zacks Investment Research has upgraded S&W Seed Company (NASDAQ: SANW) from Neutral to Outperform and maintains its $7 price target.
-
Zacks Upgrades Depomed To Outperform, $10 PT
Wednesday, August 10, 2011 - 9:09am | 24Read More...Zacks Investment Research has upgraded Depomed (NASDAQ: DEPO) from Neutral to Outperform with a $10 price target.
